abt-869
Small moleculeexperimental
Clinical trial activity
20 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
10
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2007 (NCT00486538)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 3
- Breast Neoplasms · Phase 2
- Carcinoma · Phase 3
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 2
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 2
- Digestive System Diseases · Phase 3
- Digestive System Neoplasms · Phase 3
- Endometriosis · Phase 1/Phase 2
- Liver Diseases · Phase 3
- Liver Neoplasms · Phase 3
- Macular Degeneration · Phase 2
- Neoplasms · Phase 3
- Neoplasms by Histologic Type · Phase 3
- Neoplasms by Site · Phase 3
- Neoplasms, Glandular and Epithelial · Phase 3
Mechanism of action
CSF1R inhibitor
FLT3 inhibitor
Vascular endothelial growth factor receptor inhibitor
Platelet-derived growth factor receptor inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1- Mol. weight
- 375.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL223360 ↗
Also known as
- a741439
- a 741439
- a-741439
- abt869
- abt 869
- abt-869
- abt-869
- abt-869
- abt-869
- abt-869
- al-39324
- al-39324
- al-39324
- linifanib
- linifanib
- linifanib
- linifanib
- n-(4-(3-amino-1h-indazol-4-yl)phenyl)-n1-(2-fluoro-5-methylphenyl)urea
- rg3635
- rg 3635
- rg-3635
- rg-3635
- rg-3635
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03481842 | Phase 1/Phase 2 (Phase 2) | May 3, 2018 | BioGene Life Science |
| NCT01506934 | Phase 1 | Oct 1, 2011 | Abbott |
| NCT01286974 | Phase 1 | Aug 1, 2011 | Abbott |
| NCT01365910 | Phase 2 | Jun 1, 2011 | Vanderbilt University |
| NCT01413893 | Phase 1 | Jun 1, 2011 | Abbott |
| NCT01401933 | Phase 1 | May 1, 2011 | Abbott |
| NCT01381341 | Phase 1 | May 1, 2011 | Abbott |
| NCT01225302 | Phase 1 | Sep 1, 2010 | Abbott |
| NCT00992563 | Phase 2 | Jun 1, 2010 | Alcon |
| NCT01114191 | Phase 1 | May 1, 2010 | Abbott |
| NCT01009593 | Phase 3 | Jan 1, 2010 | Abbott |
| NCT00733187 | Phase 1 | Feb 1, 2009 | AbbVie, Genentech |
| NCT00707889 | Phase 2 | Oct 1, 2008 | AbbVie, Genentech |
| NCT00718380 | Phase 1 | Sep 1, 2008 | Abbott |
| NCT00754104 | Phase 1 | Sep 1, 2008 | Abbott, Genentech |
| NCT00645177 | Phase 2 | Jul 1, 2008 | AbbVie, Genentech |
| NCT00716534 | Phase 2 | Jun 1, 2008 | AbbVie, Genentech |
| NCT00517920 | Phase 2 | Sep 1, 2007 | AbbVie, Genentech |
| NCT00517790 | Phase 2 | Aug 1, 2007 | AbbVie, Genentech |
| NCT00486538 | Phase 2 | Jun 1, 2007 | AbbVie, Genentech |
Showing 20 of 20 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abbott | For profit | 10 | 10 | 2 | 2008 |
| Genentech | For profit | 8 | 0 | 2 | 2007 |
| AbbVie | For profit | 7 | 7 | 2 | 2007 |
| Alcon | For profit | 1 | 1 | 1 | 2010 |
| BioGene Life Science | For profit | 1 | 1 | 1 | 2018 |
| Vanderbilt University | Academic/Hospital | 1 | 1 | 1 | 2011 |
6 organizations
Page 1 / 1